期刊文献+

EGFR、GnRHR和LRP在卵巢癌中的表达及临床意义 被引量:2

Expression and significance of EGFR,GnRHR and LRP in ovarian cancer
原文传递
导出
摘要 目的:探讨EGFR、GnRHR和LRP在上皮性卵巢癌中的表达及临床意义。方法:采用免疫组化S-P法检测10例正常卵巢组织、10例卵巢良性上皮性肿瘤和50例上皮性卵巢癌的石蜡包埋标本中EGFR、CmRHR和LRP的表达情况,通过统计学方法分析其表达与临床各种病理因素指标、化疗耐药及患者生存预后的关系。结果:卵巢癌中EGFR、GnRHR和LRP的表达明显高于良性组和正常组,EGFR的表达随着期别的增高而增加。EGFR表达阳性的卵巢癌术后生存率明显低于EGFR阴性表达的患者,LRP和GnRHR表达阳性的患者与表达阴性者生存率差异无统计学意义。EGFR和LRP表达阴性者化疗有效率分别明显高于二者表达阳性者。结论:EGFR在不同分期卵巢癌中的差异性表达也许可作为评判肿瘤恶性程度的指标,并可能成为卵巢癌的治疗新靶点。卵巢癌组织中GnRHR表达的阳性率与癌细胞的分化程度有一定关系,LRP在上皮性卵巢癌中的表达与化疗疗效密切相关,可用于临床预测化疗的敏感性。 Objective:To study the expressions and significance of EGFR,GnRHR and LRP in epithelial ovarian cancer. Methods:To analyze the expression of EGFR,GnRHR and LRP in 50 ovarian specimens,10 normal,and 10 benign by S-P immuno-histochemstry.All the clinical information of the patients,including the level of FIGO,the disease type,the grades of tissue differentiation,with or without lymph node metastasis,the surgery method,the effectiveness and resistance of the recent chemotherapy,and the survival rate,were collected and statistically analyzed. Results:①The positive rates of EGFR,GnRHR and LRP were significantly higher in patients with ovarian carcinoma than those with benign rumors and normal controls.②The expression of EGFR was correlated with the clinical stage.③The survival rate of the ovarian cancer surgery of patients with positive EGFR was lower than those with negative EGFR.The survival rate of the patients with positive LRP and GnRHR was same as those with negative LRP and GnRHR.The effectiveness of chemotherapy was statistically higher when EGFR and LRP expression are negative. Conclusion:①The expressions of EGFR in ovarian carcinoma are positively correlated to the level of FIGO,the malignant grade,prognosis and the effectiveness and resistance of chemotherapy.②The expression of GnRHR in ovarian cancer is related to grades of tissue differentiation.The expression level of LRP in ovarian cancers is strongly correlated to chemotherapy effectiveness and resistance.Monitoring those expressions may help predicting the sensitivity of chemotherapy.
出处 《中国妇幼保健》 CAS 北大核心 2011年第26期4074-4077,共4页 Maternal and Child Health Care of China
基金 全军医药卫生科研基金资助项目〔06MB215〕
关键词 原发性上皮性卵巢癌 表皮生长因子受体 促性腺激素释放激素受体 肺耐药蛋白 化疗耐药 Primary epithelial ovarian carcinoma EGFR GnRHR LRP Chemotherapy resistance
  • 相关文献

参考文献10

  • 1颜笑健,梁立治,曾宗渊,刘继红,袁颂华,魏梅.铂类化疗敏感型卵巢上皮癌复发的影响因素[J].癌症,2005,24(6):751-754. 被引量:14
  • 2吴令英,张蓉,黄曼妮,李宁,王桂香,刘丽影.卵巢上皮癌淋巴结转移化疗的临床疗效分析[J].癌症,2003,22(4):424-427. 被引量:6
  • 3Fresno Vara JA, Casado E, de Castro Jet al. PI3K/Akt signalling path- way and cancer [J]. Cancer Treat Rev, 2004, 30:193.
  • 4Emons G, Weiss S, Ortrdann Oet 02. LHRH might act as a negative au- tocrine regulator of proliferation of human ovarian cancer [J] . Eur J Endocrinol, 2005, 142 (6) : 665.
  • 5Volker P, Omndkcr C, Schmidt O et al. Expression of receptors for lute- inizing hormone releasing hormone cancers : frequency, autoregulation, in human ovarian and endometrlal and correlation with direct antipro- liferative activity of luteinizing hormone - releasing hormone analogues [J]. Am J Obstet Oynecol, 2002, 186 (2) : 171.
  • 6Grundker C, Volker P, Schulz KD et al. Luteinizing hormone - relea- sing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF in- duced C -fos expression in human gynecological cancers [J] . Gynecol Oncol, 2000, 78 (2) : 194.
  • 7Grtmdker C, Volker P, Emons G. Antiproliferative signaling of luteini- zing hormone releasing hormone in human endometrial and ovarian canc- er ceils through G protein alpha (I) mediated activation of phosphoty-rosine phosphatase [J]. Endocrinology, 2001, 142 (6): 2369.
  • 8Rzepka - Gorska I, Chudecka - Glaz A, Kosmider M et al. Effective- hess of combined treatment in patient with advanced ovarian carcinoma [J] . Ginekol Poi, 2002, 73 (8) : 691.
  • 9Rzepka - Gorska I, Chudecka - Glaz A, Kosmider M et al. GnRH ana- logues as an adjuvant therapy for ovarian cancer patients [ J]. Int J Gynaecol Obstet, 2003, 81 (2) : 199.
  • 10Park SJ, Armstrong S, Kim CH et al. Lack of EGF receptor contributes to drug sensitivity of human germline cells [J] . Br J Cancer, 2005, 92 : 334.

二级参考文献19

  • 1Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population [J]. J Clin Oncol, 1992,10(4) :513-514.
  • 2Rubin SC, Hoskins WJ, Saigo PE, et al. Prognostic factors for recurrence following negative second-look laparoctomy in ovarian caner patients treated with platinum-based chemotherapy[J]. Gynecol Oncol, 1991,42(2): 137-141.
  • 3Vrscaj MU, Rakar S. Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study[J]. Eur J Gynaecol Oncol, 2002,23(5):405-410.
  • 4Onda T, Kamura T, Ishizuka N, et al. Feasibility study of neoadjuvant chemotherapy followed by interval cytoreductive surgery for stage Ⅲ/Ⅳovarian, tubal and peritoneal cancers[J]. Jpn J Clin Oncol, 2004,34(1) :43-45.
  • 5Shibata K, Kikkawa F, Mika M, et al. Neoadjuvant chemotherapy for FIGO stage Ⅲ or Ⅳ ovarian cancer: Survival benefit and prognostic factors [J]. Int J Gynecol Cancer,2003,13 (5): 587-592.
  • 6Markman M. Current status of intraperitoneal therapy for ovarian cancer [J]. Curr Opin Obstet Gynecol, 1993,5(1):99-104.
  • 7Hatae M, Onishi Y, Nakamura T, et al. Neoadjuvant chemotherapy for advanced epithelial ovarian cancer [J]. Gan To Kagaku Ryoho, 2001,28(12): 1833-1837.
  • 8Vergote I. Role of surgery in ovarian cancer: an update [J].Acta Chir Belg, 2004,104 (3): 246-256.
  • 9Coukos G, Rubin SC. Early ovarian cancer [J]. Curr Treat Options Oncol, 2000,1 (2): 129-137.
  • 10Piccart MJ, Bertelsen K, Stuart G, et al. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer [J]. Int J Gynecol Cancer, 2003,13(Suppl 2):144-148.

共引文献17

同被引文献12

  • 1Losa J H,Parada Cobo C, Viniegra JG, et al. Role of the p38MAPK pathway in cisplatin-based therapy[J]. Oncogene,2003,22(26) : 3998-4006.
  • 2Brancho D, Tanaka N,Jaeschke A,et al. Mechanism of p38MAP kinase activation in vivo[J]. Genes Dev, 2003, 17(16) : 1969- 1978.
  • 3Aguirre-Ghiso JA,Ossowski L,Rosenbaum SK. Green fluores- cent protein tagging o Extracellular signal-regulated kinase and p38pathways reveals novel dynamics of pathway activation dur- ing primary and metastatic growth [J]. Cancer Res, 2004, 64(20) :7336-7345.
  • 4Mansouri A,Ridgway LD, Korapati AL, et al. Sustained activa- tion of JNK/p38MAPK pathways in response to cisplatin leads to Fas ligand induction and ceil death in ovarian carcinoma cells[J]. J Biol Chem,2003,278(21) : 19245-19256.
  • 5Van LA,Van KS,Lippen S,et al. Activation of p38MAPK is re- quired for Bax translocation to mitochondria, cytochrome c re- leaseand apoptosis induced by UVB irradiation in human kerati- nocytes[J]. FASEB .1,2004,18(15) :1946-1948.
  • 6Dabholkar M,Thomton K,Viormet J,et al. Increased mRNA levels of xeroderma pigmentosum complementation group B(XPB) and Cock- ayne s syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene(MDR1) or metallothionein- II(MT-II) in platinum-resistant human ovarian cancer ti&sues[J]. Bioe- hem Phannaeol,2000,60(11) :1611-1619.
  • 7卢洪胜,甘梅富,张艳,成斌,蔡菊芳,周涛.宫颈癌前病变及宫颈癌组织Survivin和p16^(INK4A)及p53表达的研究[J].中华肿瘤防治杂志,2009,16(11):810-813. 被引量:14
  • 8冯俊,吴云飞,徐惠绵,李建军,应荣彪.胃癌组织Survivin基因上调对Caspase-3表达影响的相关性研究[J].中华肿瘤防治杂志,2010,17(14):1083-1085. 被引量:14
  • 9李代蓉,杨燕青,田玲,王莉,马惠文,李启英,黄新华.DNA修复基因多态性与肺癌顺铂化疗敏感性的研究[J].肿瘤,2011,31(4):348-353. 被引量:11
  • 10郭智兴,林佳锐,陈智远,韦玮,郭荣平.TUBB3在体外化疗药物敏感试验肝细胞癌标本中的表达及意义[J].广东医学,2012,33(18):2750-2753. 被引量:3

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部